




Q4 & FY19 Performance Update

Q4FY19 Snapshot (Consolidated)



₹ in Millions



^{*}Revenue from Operations (which includes Other Operating Income) at Rs.6,396 mn grew by 4% in Q4FY19

Demand slowdown in Domestic business impacted growth in Q4

- Extended winter impacted the sales of summer products which account for >40% domestic business during the quarter;
- Weak rural sentiment due to low agri-price inflation;
- Adverse liquidity conditions witnessed


☐ Higher RM Costs impacted profitability

- Menthol & LLP prices increased during the year
- However, prices have cooled off from their peak.

FY19 Snapshot (Consolidated)



₹ in Millions



^{*}Revenue from Operations (which includes Other Operating Income) at Rs. 26,929 mn in FY19 grew by 6%.

☐ Kesh King, Healthcare range post strong growth after strategic initiatives in H2FY19

- Kesh King grew by 20% in H2FY19 (15% decline in FY18)
- Zandu Healthcare grew by 13% in H2FY19 (9% decline in FY18)

☐ Maintained profits despite higher RM costs and exceptional items


- Materials cost increased by 200bps
- ₹9.8 cr incurred towards VRS paid in Q3FY19

^{**}FY19 Net Sales is LTL growth (adjusted for GST in Q1)

Business Performance



BUSINESS WISE NET SALES PERFORMANCE



^{*}Note: FY19 Domestic Net sales & Brand wise sales is LTL growth (adjusted for GST in Q1)

Navratna



- ☐ Grew by **1%** during the quarter and by **8%** in FY19
 - Sales impacted due to extended winters in Q4FY19.
 - Cool Oils Market Share (vol) at 66.3% increased by 140 bps in Q4 and by
 220 bps in FY19 with Market share of 66.1%
 - Roped in Varun Dhawan to endorse Navratna Cool



Pain Management

- ☐ Pain management range grew by 1% in Q4 and by 7% in FY19.
 - Balms Market Share (vol) at 54.8% increased by 140 bps in Q4FY19 and maintained leadership with a Market Share (vol) of 54.1% in FY19

BoroPlus

emami

- ☐ Grew by **17%** in Q4 and by **2%** in FY19.
 - Antiseptic cream maintained leadership with a Market Share (vol) of
 73.5% in Q4FY19 and 73.3% in FY19



Kesh King

- ☐ Grew by **15%** in Q4 and by **13%** in FY19.
 - Q4FY19 Market Share (vol) at 26.4% grew by 220 bps and by 200
 bps in FY19 with Market share of 25.8%

Healthcare range

- ☐ Healthcare range grew by **9%** in Q4 and by **12%** in FY19
 - Growth led by Nityam and Generics & Ethicals



Male Grooming



- Male grooming range declined by **4%** in Q4. However, it grew by **3%** in FY19.
 - Fairness creams maintained leadership with a Market Share (vol) of
 64.7% in Q4FY19 and 65.0% in FY19.
 - Fairness Face wash Market Share (vol) at **14.7**% grew by **90 bps** in Q4FY19 and by **60 bps** in FY19 with a Market share of **14.4**%
 - Launched HE Magic Duo, a unique deodorant that packs two fragrances in one bottle

ADACTO DESCRIPTION OF THE PROPERTY OF THE PROP



7 Oils in One


7 Oils in One grew by 24% in Q4 and by 29% in FY19.



International Business



- □ Sales grew by **19%** in Q4 and grew by **12%** in FY19.
 - Excluding Creme 21, sales grew by 13% in Q4 and by 10% in FY19.
 - SAARC and MENAP regions performed well during the quarter
 - Market share gains across key geographies
 - Realigning marketing strategy and product formulations for Creme 21, (acquired in Jan'19) along with geographic expansion plans. Expect to post strong growth in coming quarters.



SAARC South Asian Association for Regional Cooperation (Major countries – Bangladesh, Nepal, Sri Lanka etc.)

SEA South East Asia (Major countries – Malaysia, Myanmar & Singapore)

MENAP Middle East, North Africa & Pakistan (Major countries – UAE, Qatar, Oman, Kuwait, Bahrain etc.)

CIS Commonwealth of Independent States (Major Countries – Russia, Ukraine etc.)



Financial Analysis


Q4FY19 Financial analysis



Cost of Goods Sold

(as a % of Sales)


+ 440 bps



Admin & Other Exp

(as a % of Sales)


- 90 bps



Staff Costs


(as a % of Sales)

+ 130 bps



Other Income


(₹ in Millions)



A&P Spends


(₹ in Millions)

-**50** bps



Interest Paid

(₹ in Millions)




FY19 Financial analysis



Cost of Goods Sold

(as a % of Sales)


+ 200 bps



Admin & Other Exp

(as a % of Sales)


+0 bps



Staff Costs


(as a % of Sales)

+ 40 bps



Other Income


(₹ in Millions)



A&P Spends


(₹ in Millions)

- 100 bps



Interest Paid

(₹ in Millions)



Q4FY19 Summarized Financials



₹ in Millions

Particulars Particulars	Q4FY19	%	Q4FY18	%	Growth %	FY19	%
Net Sales	6,354.2	99.3%	6,035.5	97.8%	5.3%	26,589.2	98.7%
Other Operating Income	42.2	0.7%	134.2	2.2%	-68.6%	340.2	1.3%
Revenue from Operations	6,396.4	100.0%	6,169.7	100.0%	3.7%	26,929.4	100.0%
Materials Cost	2,507.7	39.2%	2,148.8	34.8%	16.7%	9,230.1	34.3%
A&P	989.8	15.5%	987.0	16.0%	0.3%	4,701.8	17.5%
Staff Cost	680.9	10.6%	580.2	9.4%	17.4%	2,797.2	10.4%
Admn & Other Exp	670.8	10.5%	721.2	11.7%	-7.0%	2,945.0	10.9%
EBIDTA	1,547.2	24.2%	1,732.5	28.1%	-10.7%	7,255.3	26.9%
Other Income	172.6	2.7%	21.6	0.4%	699.1%	365.9	1.4%
Interest	62.1	1.0%	67.6	1.1%	-8.1%	214.0	0.8%
Amortisation of acquired TM's/ brands	650.3	10.2%	601.5	9.7%	8.1%	2,485.0	9.2%
Depreciation/Amortisation of other assets	159.7	2.5%	206.6	3.3%	-22.7%	768.2	2.9%
PBT before Exceptional Items	847.7	13.3%	878.4	14.2%	-3.5%	4,154.0	15.4%
Exceptional Items	-	0.0%	-	0.0%	0.0%	98.0	0.4%
РВТ	847.7	13.3%	878.4	14.2%	-3.5%	4,056.0	15.1%
Тах	279.8	4.4%	269.8	4.4%	3.7%	1,008.8	3.7%
PAT	567.9	8.9%	608.6	9.9%	-6.7%	3,047.2	11.3%
Share of Minority Interest & P/L of Associate	(6.4)	-0.1%	(6.3)	-0.1%	1.6%	(14.9)	-0.1%
PAT After Minority Interest & Associate	561.5	8.8%	602.3	9.8%	-6.8%	3,032.3	11.3%
Cash Profit (PAT + Dep. & Amortization)	1,371.5	21.4%	1,410.4	22.9%	-2.8%	6,285.5	23.3%
EPS - Rs.	1.24		1.33			6.68	
Cash EPS- Rs.	3.02		3.11			13.85	

FY19 Summarized Financials



₹ in Millions

Particulars	FY19	%	FY18	%	Growth %	
Net Sales	26,589.2	98.7%		98.4%	6.4%	
Other Operating Income	340.2	1.3%	•	1.6%	-16.7%	
Revenue from Operations	26,929.4	100.0%	25,408.3	100.0%	6.0%	
Materials Cost	9,230.1	34.3%	8,201.3	32.3%	12.5%	
A&P	4,701.8	17.5%	4,696.0	18.5%	0.1%	
Staff Cost	2,797.2	10.4%	2,546.5	10.0%	9.8%	
Admn & Other Exp	2,945.0	10.9%	2,770.1	10.9%	6.3%	
EBIDTA	7,255.3	26.9%	7,194.4	28.3%	0.8%	
Other Income	365.9	1.4%	195.0	0.8%	87.6%	
Interest	214.0	0.8%	343.1	1.4%	-37.6%	
Amortisation of acquired TM's/ brands	2,485.0	9.2%	2,435.8	9.6%	2.0%	
Depreciation/Amortisation of other assets	768.2	2.9%	672.8	2.6%	14.2%	
PBT before Exceptional Items	4,154.0	15.4%	3,937.7	15.5%	5.5%	
Exceptional Items	98.0	0.4%	_	0.0%	100.0%	
PBT	4,056.0	15.1%	3,937.7	15.5%	3.0%	
Тах	1,008.8	3.7%	862.6	3.4%	16.9%	
PAT	3,047.2	11.3%	3,075.1	12.1%	-0.9%	
Share of Minority Interest & P/L of Associate	(14.9)	-0.1%	(3.7)	0.0%	302.7%	
PAT After Minority Interest & Associate	3,032.3	11.3%	3,071.4	12.1%	-1.3%	
Cash Profit (PAT + Dep. & Amortization)	6,285.5	23.3%	6,180.0	24.3%	1.7%	
EPS - Rs.	6.68		6.77			
Cash EPS- Rs.	13.85		13.61			

Summarized Balance Sheet



						₹ in N	1illions	
	PARTICULARS	Consolidated				Conso	Consolidated	
S.N.		Audited Audited S		S.N.	PARTICULARS	Audited	Audited	
		As at	As at	0.14.	IMMICOLINO	As at	As at	
		31.03.2019	31.03.2018			31.03.2019	31.03.2018	
	EQUITY AND LIABILITIES				ASSETS			
	Equity			1	Non -Current Assets			
	Equity Share capital	454			Property, Plant and Equipment	7,490		
(b)	Other Equity	20,307		1	Capital work-in-progress	352		
	Total Equity attributable to owners of the company	20,761	20,136	(c)	Investment Property	548	559	
(c)	Non-Controlling Interest	(2)	6	(d)	Goodwill on Consolidation	41	41	
	Total Equity	20,759	20,142	(e)	Other Intangible Assets	8,722	9,975	
				(f)	Intangible assets under development	11	79	
	LIABILITIES			(g)	Financial Assets			
1	Non-Current Liabilities				(i) Investments			
(a)	Financial Liabilities				(a) Investment in Associate	160	182	
	(i) Other Financial Liabilities	69	83		(b) Others	1,631	1,673	
(b)	Provisions	200	238		(ii) Loans	142	119	
(c)	Deferred tax liabilities (Net)	160	147	•	(iii) Other Non-Current Financial assets	291	272	
(d)	Other Non-Current Liabilities	237	258		Deferred tax Assets (net)	38	29	
		666	726	(i)	Other Non-Current Assets	177		
						19,730	21,000	
2	Current liabilities			2	Current assets			
(a)	Financial Liabilities			l ` ′	Inventories	2,217	1,940	
	(i) Borrowings	1,099	3,259	(b)	Financial Assets			
	(ii) Trade Payables				(i) Investments	79	1,281	
	Total oustanding dues of Micro, Small & Medium Enterprises (MSME)	30	13		(ii) Trade Receivables	2,164	1,559	
	Total oustanding dues of creditors Others than MSME	2,883	2,407		(iii) Cash & Cash Equivalents	1,165	162	
	(iii) Other Financial Liabilities	1,326	598		(iv) Bank Balances other than (iii) above	869	633	
(b)	Other Current Liabilities	245	222		(v) Loans	47	30	
(c)	Provisions	1,153	622		(vi) Other Financial Assets	498	568	
(d)	Current Tax Liabilities (Net)	63		. ` ′	Other Current Assets	1,455		
		6,799	1			8,493	7,008	
	Total Equity and Liabilities	28,224	28,007		Total Assets	28,224	28,007	

Awards & Accolades



☐ Received the prestigious 'Golden Peacock Innovative Product/Service Award' for the year 2019 for "Kesh King Oil Applicator"

☐ Boroplus ranked **91st** among the **Top 100 Brands** in the **Economic Times Brand Equity -Most Trusted Brands, 2018** survey conducted by Nielsen across categories



 BoroPlus, Zandu, Navratna and Fair and Handsome were also ranked 25th, 27th, 30th and 50th positions in the Health & Personal Care Category respectively



